Ionization detail - biologically based treatment planning for particle therapy beyond let-RBE

Active Project Grant Awarded Last action

Award ID
R01CA266467
Recipient
Awarding agency
Obligated
$3,720,776

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 84% complete
Place of performance
San Francisco, CA 94143, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Current proton and ION therapy treatment planning procedures utilize either the physical quantity linear energy transfer (let) as a surrogate for biological effectiveness or make use of relative biological effectiveness (RBE) models that convert absorbed dose to biologically weighted dose, assumed to be ISO- effective to photons. Let is indeed important clinically for planning treatments with charged particles, but there are known problems. ION beams with the same let can have different RBE, depending on particle type and energy. Therefore, let by itself is not an ideal parameter to use in radiation treatment planning (RTP). For clinical application of carbon therapy, RBE-models have been developed. However, comparisons of different RBE models used for carbon therapy have shown that dose prescriptions implemented with the european local effect model or the japanese national institute of radiological sciences mixed beam model can be up to 15% different. We use the term ionization detail (ID) to mean the detailed distribution of ionizing events along a particle track on the nanometer scale. Our chief hypothesis, which is supported by strong prior evidence, is that ID can predict, better than let and existing RBE models, the biological effects associated with high-let radiation. We have previously shown how ID can be used together with these models to improve their performance, providing a path for integrating ID-based RTP into clinical practice. Our approach could lead to a consensus in proton and ION therapy RTP. With four specific aims, we have chosen a translational and stepwise approach to build an ID-based prediction model. We will test this model for different endpoints and model systems ranging from in vitro cell and molecular data, obtained by irradiating human cancer cells in flasks and anatomical phantoms, to in vivo mice/human tumor data. We will develop advanced algorithms and computational GPU- based methods and use them for effective inverse treatment planning with actively scanned proton and ION beams. This technology will be applied to demonstrate the practicality and evaluate the clinical efficacy of our approach in prostate and chordoma treatments, first prospectively in human-size pelvis and head phantoms, and finally, retrospectively in patients treated for these diseases. We have assembled a strong team with the complementary expertise needed for this project. Members of our team have all successfully collaborated together. Upon completion, we will provide a rigorously tested and validated approach to ID-based particle RTP that will be available for cross-correlation with existing clinical data and for careful testing in prospective clinical particle therapy trials.

Transactions

Action Obligated Date
Amendment $595,665
Amendment $595,574
Amendment $566,612
Amendment $581,657
Amendment $690,634
Original award $690,634

Subawards

Subrecipient Amount Awarded
Mayo Clinic Jacksonville (A Nonprofit Corporation) Dr. Beltran will be performing in-vitro radiation experiments and microdosimetry measurements at the Mayo Clinic Florida Particle Therapy Facility with both… $78,750
University Of Haifa Project Goals. This project has a 5-year budget for the University of Haifa to support work on development of a practical approach to biologically-based… $85,339
Universitätsklinikum Heidelberg As co-PIs, Drs. Dokic and Moustafa will synergistically be responsible for supervising here proposed project to successfully carry out the specific aims. Dr.… $210,512
Loma Linda University Overview This five-year R01 grant from the National Institute of Health/National Cancer Institute brings together a multidisciplinary project team from the… $202,925
Deutsches Krebsforschungszentrum Dr. Oliver Jaekel is the PI at the DKFZ. Dr. Jaekel will take primary responsibility for the management of all aspects of the scientific work packages performed… $182,104
Baylor University The Baylor team composed of Dr. Schubert and his graduate student will support the grant by working on Aim 2: Aim 2. Develop practical ID-based proton and… $117,873

Quick answers

Who received award R01CA266467?

R01CA266467 was awarded to The Regents Of The University Of California. San Francisco by National Cancer Institute (National Institutes of Health) on September 1, 2022.

How much is award R01CA266467 worth?

$3,720,776 has been obligated on R01CA266467.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login